Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz239.062
Abstract: Abstract Background Inflammation has a significant impact on cervical cancer (CC) development and therapy response. We sought to determine if splenic metabolic activity reflects host immune status and could improve prognostic and predictive categorization of… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz242.046
Abstract: Abstract Background Both pertuzumab and T-DM1 improved overall survival (OS) of HER2+ metastatic breast cancer (MBC) in clinical trials. Little is known about their activity outside of clinical trials and when administered sequentially or after… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.047
Abstract: Abstract Background FOLFOXIRI + bev is regarded as a valuable option in the first-line tx of mCRC pts. A possible concern for the adoption is the feasibility and efficacy of tx after progression, and especially… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz249.005
Abstract: Abstract Background In the S-TRAC trial, adjuvant sunitinib (SU) prolonged disease-free survival (DFS) versus placebo (PBO) in patients (pts) with loco-regional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy. We previously applied… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz249.043
Abstract: Abstract Background Tivozanib is a VEGFR-TKI with high specificity and lower incidence of class effect adverse events. We have previously reported encouraging preliminary results for objective response rates and tolerability for tivozanib and nivolumab at… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz249.062
Abstract: Abstract Background Nivolumab is a standard of care in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after failure of prior anti-angiogenic tyrosine-kinase inhibitors (TKIs). We evaluated the impact of corticosteroids (CS) during… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz252.002
Abstract: Abstract Background The main challenges in patients (pts) > = 70y are to cope with the treatment benefit/risk ratio and tumor related symptoms; no standard systemic treatment has been validated. With GERICO-GORTEC groups, we developed a large… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz253.080
Abstract: Abstract Background An elevated pre-treatment Neutrophil to Lymphocytes Ratio (NLR) is associated with poor prognosis in various malignancies. As optimal cut-off is highly variable and few data have been reported in patients treated with anti-PD-1,… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz256.004
Abstract: Abstract Background Sunitinib (SUN) is approved for the treatment of advanced progressive pNETs. Hypoxia induced by SUN could foster the activation of the prodrug evofosfamide (EVO), designed to release the DNA alkylator bromo-isophosphoramide mustard under… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz256.006
Abstract: Abstract Background Tumor proliferation and grade are important prognostic factors at diagnosis of PNETs. Little is known about how these factors change over time and if longitudinal increase in Ki67-index is associated with prognosis. The… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz260.076
Abstract: Abstract Background Amplifications in FGFR1are a potential target to therapy with FGFR inhibitors in squamous cell carcinoma NSCLC (SqCC). Recent insights in other entities demonstrate that the efficacy of these inhibitors is not limited to… read more here.